Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11114800 | 0.85 | TSHR (0.55) | TSHRCYP2C19CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10623825 | 0.85 | CA2 (0.57) | TSHRCYP2C19CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL20511401 | 0.85 | TSHR (0.54) | TSHRCYP2C19CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2883933 | 0.83 | PRMT5 (0.49) | TSHRCYP2C19CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6674437 | 0.83 | TSHR (0.59) | TSHRCYP2C19CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1969838 | 0.82 | CYP1A2 (0.58) | TSHRCYP2C19CYP1A2CYP19A1CYP3A4 | |
| SCHEMBL874787 | 0.81 | TSHR (0.51) | TSHRCYP19A1 | |
| SCHEMBL10556974 | 0.81 | CYP2C19 (0.45) | TSHRCYP2C19CYP1A2CYP2D6CYP2C9 | |
| Dinitrophenylene SCHEMBL27570678 | 0.79 | CYP19A1 (0.53) | TSHRCYP2C19CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL3841606 | 0.79 | CYP1A2 (0.49) | TSHRCYP2C19CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442947-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | Epizyme Inc (US) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017181177-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2017-10-19 | — | — | WO | disclosed |
| EP-2010528-B1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| EP-2010528-B1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8710048-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-8710048-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-8710048-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| CN-101432281-B | 6-0-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG | 2013-08-28 | — | — | CN | disclosed |
| US-8461134-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| EP-1569637-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | Abbott Laboratories (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005014552-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| US-20050027009-A1 | New derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2005-02-03 | — | — | US | disclosed |
| US-6809090-B2 | NITROGEN MONOXIDE SYNTHASE AND/OR LIPIDIC PEROXIDATION INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2004-10-26 | — | — | US | disclosed |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004043458-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040097494-A1 | New derivatives of N-(iminomethy)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2004-05-20 | — | — | US | disclosed |
| US-20040092521-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES | 2004-05-13 | — | — | US | disclosed |
| US-6620840-B1 | Nitric oxide synthase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-09-16 | — | — | US | disclosed |
| US-6482822-B1 | N-(iminomethyl)amines derivatives, their preparation, their use as medicines and compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050027009-A1 | New derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | NOS1, NOS2, NOS3 | TSHR 2025/4885CYP2C19 363/4885CYP1A2 337/4885 |
| US-20040092521-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | TSHR 431/4885CYP2C19 1062/4885CYP1A2 1015/4885 |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | TSHR 361/4885CYP2C19 799/4885CYP1A2 838/4885 |
| US-20040097494-A1 | New derivatives of N-(iminomethy)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | NOS1, NOS2, NOS3 | TSHR 1551/4885CYP2C19 389/4885CYP1A2 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.